A History of Bold Action
Forging our future on the foundation of a BOLD past
Amarin is built on a history of bold actions. Read below for highlights of our history as a company committed to being BOLD.
2008
Amarin Opens Research and Development Center
2009
AMARIN RECEIVES SPA FOR PHASE 3 MARINE STUDY
2011
AMARIN COMMENCES 1ST PATIENT IN REDUCE-IT™ Trial
2011
2012
AMARIN RECEIVES FDA APPROVAL FOR VASCEPA® (ICOSAPENT ETHYL)
2012
2013
Amarin launches commercially in the U.S.
2013
2008
Amarin Opens Research and Development Center
Amarin makes its entry into cardiovascular research and development and opens its R&D headquarters in Mystic, Connecticut.
2009
AMARIN RECEIVES SPA FOR PHASE 3 MARINE STUDY
Receives Special Protocol Assessment for its Phase 3 MARINE study evaluating AMR-101’s ability to lower triglycerides.
2011
2011
AMARIN COMMENCES 1ST PATIENT IN REDUCE-IT™ Trial
Commences first patient in REDUCE-IT, The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial.”
Get to know Amarin
Who is Amarin? Amarin is a global pharmaceutical company that has developed and is pursuing additional treatments to help address cardiovascular disease. Amarin is relentless in its pursuit of scientific breakthroughs that can lead to revolutionary solutions that create a healthier world. Find out more about who we are, what we stand for and how we are making a difference in the lives of patients.
Where we are
Amarin is making a positive impact on cardiovascular health across the world. Find out where we're located.
Contact Us
Amarin seeks to collaborate with others to address cardiovascular risk and create value.
Company Profile
A rapidly growing, international leader in the fight to address cardiovascular disease
Amarin focuses on a BOLD vision to stop cardiovascular disease from being a leading cause of death worldwide.
